Skip to main content
SpringerLink
Log in
Book cover

Allogeneic Stem Cell Transplantation pp 597–618Cite as

Post-transplant Lymphoproliferative Disorder

  • Chapter
  • First Online:

  • 1443 Accesses

Part of the book series: Contemporary Hematology ((CH))

Abstract

The increased risk of malignancy, especially of lymphoid tumors, in solid-organ and hematopoietic stem cell transplant (HST) recipients has been recognized for many years [1-3]. Post-transplant lymphoproliferative disorder (PTLD) represents a heterogeneous group of abnormal lymphoid proliferations, generally of B-cell origin, that occur in the setting of ineffective T-cell function due to pharmacologic immunosuppression after organ transplantation. Unlike most other forms of non-Hodgkin’s lymphoma, nearly all PTLD is associated with Epstein-Barr virus (EBV) infection, as manifested by the presence of EBV within the malignant tissue.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   119.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   159.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Murray JE et al (1968) Five years’ experience in renal transplantation with immunosuppressive drugs: Survival, function, complications, and the role of lymphocyte depletion by thoracic duct fistula. Ann Surg 168(3):416-435

    PubMed  CAS  Google Scholar 

  2. Penn I et al (1969) Malignant lymphomas in transplantation patients. Transplant Proc 1(1):106-112

    PubMed  CAS  Google Scholar 

  3. Bhatia S et al (1996) Malignant neoplasms following bone marrow transplantation. Blood 87(9):3633-3639

    PubMed  CAS  Google Scholar 

  4. Nalesnik MA (1996) Posttransplantation lymphoproliferative disorders (PTLD): Current perspectives. Semin Thorac Cardiovasc Surg 8(2):139-148

    PubMed  CAS  Google Scholar 

  5. Frizzera G et al (1981) Polymorphic diffuse B-cell hyperplasias and lymphomas in renal transplant recipients. Cancer Res 41(11 Pt 1):4262-4279

    PubMed  CAS  Google Scholar 

  6. Knowles DM et al (1995) Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders. Blood 85(2):552-565

    PubMed  CAS  Google Scholar 

  7. Paya CV et al (1999) Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting. Transplantation 68(10):1517-1525

    PubMed  CAS  Google Scholar 

  8. Harris NL, Ferry JA, Swerdlow SH (1997) Posttransplant lymphoproliferative disorders: Summary of Society for Hematopathology Workshop. Semin Diagn Pathol 14(1):8-14

    PubMed  CAS  Google Scholar 

  9. Harris NL et al (1999) World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 17(12):3835-3849

    PubMed  CAS  Google Scholar 

  10. Harris NL et al (1994) A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood 84(5):1361-1392

    PubMed  CAS  Google Scholar 

  11. Epstein MA, Achong BG, Barr YM (1964) Virus particles in cultured lymphoblasts from Burkitt’s lymphoma. Lancet 1:702-703

    PubMed  CAS  Google Scholar 

  12. Williams H, Crawford DH (2006) Epstein-Barr virus: The impact of scientific advances on clinical practice. Blood 107(3):862-869

    PubMed  CAS  Google Scholar 

  13. Thorley-Lawson DA, Gross A (2004) Persistence of the Epstein-Barr virus and the origins of associated lymphomas. N Engl J Med 350(13):1328-1337

    PubMed  CAS  Google Scholar 

  14. Zutter MM et al (1988) Epstein-Barr virus lymphoproliferation after bone marrow transplantation. Blood 72(2):520-529

    PubMed  CAS  Google Scholar 

  15. Shapiro RS et al (1988) Epstein-Barr virus associated B cell lymphoproliferative disorders following bone marrow transplantation. Blood 71(5):1234-1243

    PubMed  CAS  Google Scholar 

  16. Parry-Jones N et al (1999) Epstein-Barr virus (EBV) associated B-cell lymphoproliferative disease following HLA identical sibling marrow transplantation for aplastic anaemia in a patient with an EBV seronegative donor. Transplantation 67(10):1373-1375

    PubMed  CAS  Google Scholar 

  17. Nalesnik MA, Makowka L, Starzl TE (1988) The diagnosis and treatment of posttransplant lymphoproliferative disorders. Curr Probl Surg 25(6):367-472

    PubMed  CAS  Google Scholar 

  18. Opelz G, Dohler B (2004) Lymphomas after solid organ transplantation: A collaborative transplant study report. Am J Transplant 4(2):222-230

    PubMed  Google Scholar 

  19. Katz BZ et al (2007) Case-control study of risk factors for the development of post-transplant lymphoproliferative disease in a pediatric heart transplant cohort. Pediatr Transplant 11(1):58-65

    PubMed  CAS  Google Scholar 

  20. Penn I (2000) Post-transplant malignancy: The role of immunosuppression. Drug Saf 23(2):101-113

    PubMed  CAS  Google Scholar 

  21. Nalesnik MA (1997) Clinicopathologic features of posttransplant lymphoproliferative disorders. Ann Transplant 2(4):33-40

    PubMed  CAS  Google Scholar 

  22. Swinnen LJ et al (1990) Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. N Engl J Med 323(25):1723-1728

    PubMed  CAS  Google Scholar 

  23. Bustami RT et al (2004) Immunosuppression and the risk of post-transplant malignancy among cadaveric first kidney transplant recipients. Am J Transplant 4(1):87-93

    PubMed  Google Scholar 

  24. Gross TG et al (1999) B cell lymphoproliferative disorders following hematopoietic stem cell transplantation: Risk factors, treatment and outcome. Bone Marrow Transplant 23(3):251-258

    PubMed  CAS  Google Scholar 

  25. Micallef IN et al (1998) Lymphoproliferative disorders following allogeneic bone marrow transplantation: The Vancouver experience. Bone Marrow Transplant 22(10):981-987

    PubMed  CAS  Google Scholar 

  26. Curtis RE et al (1999) Risk of lymphoproliferative disorders after bone marrow transplantation: A multi-institutional study. Blood 94(7):2208-2216

    PubMed  CAS  Google Scholar 

  27. Cohen JM et al (2007) EBV-related disease following haematopoietic stem cell transplantation with reduced intensity conditioning. Leuk Lymphoma 48(2):256-269

    PubMed  Google Scholar 

  28. Herzig KA et al (2003) A single-centre experience of post-renal transplant lymphoproliferative disorder. Transpl Int 16(7):529-536

    PubMed  Google Scholar 

  29. Barker JN et al (2001) Low incidence of Epstein-Barr virus-associated posttransplantation lymphoproliferative disorders in 272 unrelated-donor umbilical cord blood transplant recipients. Biol Blood Marrow Transplant 7(7):395-399

    PubMed  CAS  Google Scholar 

  30. Hauke RJ et al (1998) Epstein-Barr virus-associated lymphoproliferative disorder after autologous bone marrow transplantation: Report of two cases. Bone Marrow Transplant 21(12):1271-1274

    PubMed  CAS  Google Scholar 

  31. Shepherd JD et al (1995) Polyclonal Epstein-Barr virus-associated lymphoproliferative disorder following autografting for chronic myeloid leukemia. Bone Marrow Transplant 15(4):639-641

    PubMed  CAS  Google Scholar 

  32. Lones MA et al (2000) Post-transplant lymphoproliferative disorder after autologous peripheral stem cell transplantation in a pediatric patient. Bone Marrow Transplant 26(9):1021-1024

    PubMed  CAS  Google Scholar 

  33. Nash RA et al (2003) Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder after high-dose immunosuppressive therapy and autologous CD34-selected hematopoietic stem cell transplantation for severe autoimmune diseases. Biol Blood Marrow Transplant 9(9):583-591

    PubMed  Google Scholar 

  34. Crawford DH et al (1986) Epstein-Barr virus infection and immunity in bone marrow transplant recipients. Transplantation 42(1):50-54

    PubMed  CAS  Google Scholar 

  35. Lucas KG et al (1996) The development of cellular immunity to Epstein-Barr virus after allogeneic bone marrow transplantation. Blood 87(6):2594-2603

    PubMed  CAS  Google Scholar 

  36. Marshall NA et al (2000) Rapid reconstitution of Epstein-Barr virus-specific T lymphocytes following allogeneic stem cell transplantation. Blood 96(8):2814-2821

    PubMed  CAS  Google Scholar 

  37. Small TN et al (1999) Comparison of immune reconstitution after unrelated and related T-cell-depleted bone marrow transplantation: Effect of patient age and donor leukocyte infusions. Blood 93(2):467-480

    PubMed  CAS  Google Scholar 

  38. Leblond V et al (1998) Posttransplant lymphoproliferative disorders not associated with Epstein-Barr virus: A distinct entity? J Clin Oncol 16(6):2052-2059

    PubMed  CAS  Google Scholar 

  39. Nelson BP et al (2000) Epstein-Barr virus-negative post-transplant lymphoproliferative disorders: A distinct entity? Am J Surg Pathol 24(3):375-385

    PubMed  CAS  Google Scholar 

  40. Hezode C et al (1999) Role of hepatitis C virus in lymphoproliferative disorders after liver transplantation. Hepatology 30(3):775-778

    PubMed  CAS  Google Scholar 

  41. McLaughlin K et al (2000) Increased risk for posttransplant lymphoproliferative disease in recipients of liver transplants with hepatitis C. Liver Transpl 6(5):570-574

    PubMed  CAS  Google Scholar 

  42. Buda A et al (2000) Lymphoproliferative disorders in heart transplant recipients: Role of hepatitis C virus (HCV) and Epstein-Barr virus (EBV) infection. Transpl Int 13(Suppl 1):S402-S405

    Google Scholar 

  43. Morton LM et al (2007) Hepatitis C virus infection and risk of posttransplantation lymphoproliferative disorder among solid organ transplant recipients. Blood 110(13):4599-4605

    PubMed  CAS  Google Scholar 

  44. Cockfield SM (2001) Identifying the patient at risk for post-transplant lymphoproliferative disorder. Transpl Infect Dis 3(2):70-78

    PubMed  CAS  Google Scholar 

  45. Bakker NA et al (2007) Presentation and early detection of post-transplant lymphoproliferative disorder after solid organ transplantation. Transpl Int 20(3):207-218

    PubMed  CAS  Google Scholar 

  46. Taylor AL, Marcus R, Bradley JA (2005) Post-transplant lymphoproliferative disorders (PTLD) after solid organ transplantation. Crit Rev Oncol Hematol 56(1):155-167

    PubMed  Google Scholar 

  47. Gottschalk S, Rooney CM, Heslop HE (2005) Post-transplant lymphoproliferative disorders. Annu Rev Med 56:29-44

    PubMed  CAS  Google Scholar 

  48. Tsai DE et al (2001) Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: Analysis of prognostic variables and long-term follow-up of 42 adult patients. Transplantation 71(8):1076-1088

    PubMed  CAS  Google Scholar 

  49. Kaleem Z et al (2004) Flow cytometric evaluation of posttransplant B-cell lymphoproliferative disorders. Arch Pathol Lab Med 128(2):181-186

    PubMed  Google Scholar 

  50. Djokic M et al (2006) Post-transplant lymphoproliferative disorder subtypes correlate with different recurring chromosomal abnormalities. Genes Chromosomes Cancer 45(3):313-318

    PubMed  CAS  Google Scholar 

  51. Poirel HA et al (2005) Characteristic pattern of chromosomal imbalances in posttransplantation lymphoproliferative disorders: Correlation with histopathological subcategories and EBV status. Transplantation 80(2):176-184

    PubMed  Google Scholar 

  52. Vakiani E et al (2007) Cytogenetic analysis of B-cell posttransplant lymphoproliferations validates the World Health Organization classification and suggests inclusion of florid follicular hyperplasia as a precursor lesion. Hum Pathol 38(2):315-325

    PubMed  Google Scholar 

  53. Tsai DE et al (2005) Serum protein electrophoresis abnormalities in adult solid organ transplant patients with post-transplant lymphoproliferative disorder. Clin Transplant 19(5):644-652

    PubMed  Google Scholar 

  54. Benkerrou M, Durandy A, Fischer A (1993) Therapy for transplant-related lymphoproliferative diseases. Hematol Oncol Clin North Am 7(2):467-475

    PubMed  CAS  Google Scholar 

  55. Benkerrou M et al (1998) Anti-B-cell monoclonal antibody treatment of severe posttransplant B-lymphoproliferative disorder: Prognostic factors and long-term outcome. Blood 92(9):3137-3147

    PubMed  CAS  Google Scholar 

  56. Riddler SA, Breinig MC, McKnight JL (1994) Increased levels of circulating Epstein-Barr virus (EBV)-infected lymphocytes and decreased EBV nuclear antigen antibody responses are associated with the development of posttransplant lymphoproliferative disease in solid-organ transplant recipients. Blood 84(3):972-984

    PubMed  CAS  Google Scholar 

  57. Savoie A et al (1994) Direct correlation between the load of Epstein-Barr virus-infected lymphocytes in the peripheral blood of pediatric transplant patients and risk of lymphoproliferative disease. Blood 83(9):2715-2722

    PubMed  CAS  Google Scholar 

  58. Rooney CM et al (1995) Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 345(8941):9-13

    PubMed  CAS  Google Scholar 

  59. Kenagy DN et al (1995) Epstein-Barr virus DNA in peripheral blood leukocytes of patients with posttransplant lymphoproliferative disease. Transplantation 60(6):547-554

    PubMed  CAS  Google Scholar 

  60. Lucas KG et al (1998) Semiquantitative Epstein-Barr virus (EBV) polymerase chain reaction for the determination of patients at risk for EBV-induced lymphoproliferative disease after stem cell transplantation. Blood 91(10):3654-3661

    PubMed  CAS  Google Scholar 

  61. McDiarmid SV et al (1998) Prevention and preemptive therapy of postransplant lymphoproliferative disease in pediatric liver recipients. Transplantation 66(12):1604-1611

    PubMed  CAS  Google Scholar 

  62. Rooney CM et al (1995) Early identification of Epstein-Barr virus-associated post-transplantation lymphoproliferative disease. Br J Haematol 89(1):98-103

    PubMed  CAS  Google Scholar 

  63. Green M et al (2000) Predictive negative value of persistent low Epstein-Barr virus viral load after intestinal transplantation in children. Transplantation 70(4):593-596

    PubMed  CAS  Google Scholar 

  64. Tsai DE et al (2002) Use of EBV PCR for the diagnosis and monitoring of post-transplant lymphoproliferative disorder in adult solid organ transplant patients. Am J Transplant 2(10):946-954

    PubMed  Google Scholar 

  65. Yang J et al (2000) Characterization of Epstein-Barr virus-infected B cells in patients with posttransplantation lymphoproliferative disease: Disappearance after rituximab therapy does not predict clinical response. Blood 96(13):4055-4063

    PubMed  CAS  Google Scholar 

  66. Kinch A et al (2007) Post-transplant lymphoproliferative disease and other Epstein-Barr virus diseases in allogeneic haematopoietic stem cell transplantation after introduction of monitoring of viral load by polymerase chain reaction. Scand J Infect Dis 39(3):235-244

    PubMed  CAS  Google Scholar 

  67. van Esser JW et al (2002) Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. Blood 99(12):4364-4369

    PubMed  Google Scholar 

  68. Wagner HJ et al (2004) Prompt versus preemptive intervention for EBV lymphoproliferative disease. Blood 103(10):3979-3981

    PubMed  CAS  Google Scholar 

  69. Humar A, Michaels M (2006) American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. Am J Transplant 6(2):262-274

    PubMed  CAS  Google Scholar 

  70. Colby BM et al (1980) Effect of acyclovir [9-(2-hydroxyethoxymethyl)guanine] on Epstein-Barr virus DNA replication. J Virol 34(2):560-568

    PubMed  CAS  Google Scholar 

  71. Crumpacker CS (1996) Ganciclovir. N Engl J Med 335(10):721-729

    PubMed  CAS  Google Scholar 

  72. Faller DV, Mentzer SJ, Perrine SP (2001) Induction of the Epstein-Barr virus thymidine kinase gene with concomitant nucleoside antivirals as a therapeutic strategy for Epstein-Barr virus-associated malignancies. Curr Opin Oncol 13(5):360-367

    PubMed  CAS  Google Scholar 

  73. Perrine SP et al (2007) A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies. Blood 109(6):2571-2578

    PubMed  CAS  Google Scholar 

  74. Darenkov IA et al (1997) Reduced incidence of Epstein-Barr virus-associated posttransplant lymphoproliferative disorder using preemptive antiviral therapy. Transplantation 64(6):848-852

    PubMed  CAS  Google Scholar 

  75. Davis CL et al (1995) Antiviral prophylaxis and the Epstein Barr virus-related post-transplant lymphoproliferative disorder. Clin Transplant 9(1):53-59

    PubMed  CAS  Google Scholar 

  76. (2002) European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.6.2. Cancer risk after renal transplantation. Skin cancers: Prevention and treatment. Nephrol Dial Transplant 17 (Suppl 4):31-66

    Google Scholar 

  77. Davis CL et al (1998) Interferon-alpha treatment of posttransplant lymphoproliferative disorder in recipients of solid organ transplants. Transplantation 66(12):1770-1779

    PubMed  CAS  Google Scholar 

  78. Dotti G et al (2002) Lymphomas occurring late after solid-organ transplantation: Influence of treatment on the clinical outcome. Transplantation 74(8):1095-1102

    PubMed  Google Scholar 

  79. Koffman BH et al (2000) Use of radiation therapy in posttransplant lymphoproliferative disorder (PTLD) after liver transplantation. Int J Cancer 90(2):104-109

    PubMed  CAS  Google Scholar 

  80. Hauke R et al (2001) Clinical and pathological features of posttransplant lymphoproliferative disorders: Influence on survival and response to treatment. Ann Oncol 12(6):831-834

    PubMed  CAS  Google Scholar 

  81. Elstrom RL et al (2006) Treatment of PTLD with rituximab or chemotherapy. Am J Transplant 6(3):569-576

    PubMed  CAS  Google Scholar 

  82. Kang SK, Kirkpatrick JP, Halperin EC (2003) Low-dose radiation for posttransplant lymphoproliferative disorder. Am J Clin Oncol 26(2):210-214

    PubMed  Google Scholar 

  83. Starzl TE et al (1984) Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet 1(8377):583-587

    PubMed  CAS  Google Scholar 

  84. Loren AW, Tsai DE (2005) Post-transplant lymphoproliferative disorder. Clin Chest Med 26(4):631-645 vii

    PubMed  Google Scholar 

  85. Frey NV, Tsai DE (2007) The management of posttransplant lymphoproliferative disorder. Med Oncol 24(2):125-136

    PubMed  CAS  Google Scholar 

  86. Shan D, Ledbetter JA, Press OW (1998) Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood 91(5):1644-1652

    PubMed  CAS  Google Scholar 

  87. Di Gaetano N et al (2003) Complement activation determines the therapeutic activity of rituximab in vivo. J Immunol 171(3):1581-1587

    PubMed  Google Scholar 

  88. Svoboda J, Kotloff R, Tsai DE (2006) Management of patients with post-transplant lymphoproliferative disorder: The role of rituximab. Transpl Int 19(4):259-269

    PubMed  CAS  Google Scholar 

  89. Choquet S et al (2006) Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: Results of a prospective multicenter phase 2 study. Blood 107(8):3053-3057

    PubMed  CAS  Google Scholar 

  90. Milpied N et al (2000) Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: A retrospective analysis on 32 patients. Ann Oncol 11(Suppl 1):113-116

    PubMed  Google Scholar 

  91. Oertel SH et al (2005) Effect of anti-CD 20 antibody rituximab in patients with post-transplant lymphoproliferative disorder (PTLD). Am J Transplant 5(12):2901-2906

    PubMed  CAS  Google Scholar 

  92. Sharman JP et al (2006) Mature results of a prospective trial of rituximab in patients (Pt) with post transplant lymphoproliferative disorder (PTLD) unresponsive or ineligible for reduced immunosuppression (RIS). ASH Annu Meet Abstr 108(11):2755

    Google Scholar 

  93. Faye A et al (2001) Chimaeric anti-CD20 monoclonal antibody (rituximab) in post-transplant B-lymphoproliferative disorder following stem cell transplantation in children. Br J Haematol 115(1):112-118

    PubMed  CAS  Google Scholar 

  94. Orjuela M et al (2003) A pilot study of chemoimmunotherapy (cyclophosphamide, prednisone, and rituximab) in patients with post-transplant lymphoproliferative disorder following solid organ transplantation. Clin Cancer Res 9(10 Pt 2):3945S-3952S

    PubMed  CAS  Google Scholar 

  95. Faro A et al (1996) Interferon-alpha affects the immune response in post-transplant lymphoproliferative disorder. Am J Respir Crit Care Med 153(4 Pt 1):1442-1447

    PubMed  CAS  Google Scholar 

  96. Tosato G et al (1993) Interleukin-6 production in posttransplant lymphoproliferative disease. J Clin Invest 91(6):2806-2814

    PubMed  CAS  Google Scholar 

  97. Tosato G et al (1990) Identification of interleukin-6 as an autocrine growth factor for Epstein-Barr virus-immortalized B cells. J Virol 64(6):3033-3041

    PubMed  CAS  Google Scholar 

  98. Haddad E et al (2001) Treatment of B-lymphoproliferative disorder with a monoclonal anti-interleukin-6 antibody in 12 patients: A multicenter phase 1-2 clinical trial. Blood 97(6):1590-1597

    PubMed  CAS  Google Scholar 

  99. Swinnen LJ et al (1995) Aggressive treatment for postcardiac transplant lymphoproliferation. Blood 86(9):3333-3340

    PubMed  CAS  Google Scholar 

  100. Mamzer-Bruneel MF et al (2000) Durable remission after aggressive chemotherapy for very late post-kidney transplant lymphoproliferation: A report of 16 cases observed in a single center. J Clin Oncol 18(21):3622-3632

    PubMed  CAS  Google Scholar 

  101. Buell JF et al (2005) Chemotherapy for posttransplant lymphoproliferative disorder: The Israel Penn International Transplant Tumor Registry experience. Transplant Proc 37(2):956-957

    PubMed  CAS  Google Scholar 

  102. Gross TG et al (2005) Low-dose chemotherapy for Epstein-Barr virus-positive post-transplantation lymphoproliferative disease in children after solid organ transplantation. J Clin Oncol 23(27):6481-6488

    PubMed  CAS  Google Scholar 

  103. Oertel SH et al (2003) Salvage chemotherapy for refractory or relapsed post-transplant lymphoproliferative disorder in patients after solid organ transplantation with a combination of carboplatin and etoposide. Br J Haematol 123(5):830-835

    PubMed  CAS  Google Scholar 

  104. Komrokji RS et al (2005) Mini-BEAM and autologous hematopoietic stem-cell transplant for treatment of post-transplant lymphoproliferative disorders. Am J Hematol 79(3):211-215

    PubMed  Google Scholar 

  105. Bobey NA, Stewart DA, Woodman RC (2002) Successful treatment of posttransplant lymphoproliferative disorder in a renal transplant patient by autologous peripheral blood stem cell transplantation. Leuk Lymphoma 43(12):2421-2423

    PubMed  CAS  Google Scholar 

  106. Kook H et al (1996) Reconstruction of the immune system after unrelated or partially matched T-cell-depleted bone marrow transplantation in children: Immunophenotypic analysis and factors affecting the speed of recovery. Blood 88(3):1089-1097

    PubMed  CAS  Google Scholar 

  107. Kuzushima K et al (2000) Longitudinal dynamics of Epstein-Barr virus-specific cytotoxic T lymphocytes during posttransplant lymphoproliferative disorder. J Infect Dis 182(3):937-940

    PubMed  CAS  Google Scholar 

  108. Khatri VP et al (1999) Endogenous CD8+ T cell expansion during regression of monoclonal EBV-associated posttransplant lymphoproliferative disorder. J Immunol 163(1):500-506

    PubMed  CAS  Google Scholar 

  109. Porter DL, Orloff GJ, Antin JH (1994) Donor mononuclear cell infusions as therapy for B-cell lymphoproliferative disorder following allogeneic bone marrow transplant. Transplant Sci 4(1):12-14 discussion 14-6

    PubMed  CAS  Google Scholar 

  110. Papadopoulos EB et al (1994) Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med 330(17):1185-1191

    PubMed  CAS  Google Scholar 

  111. O'Reilly RJ et al (1997) Biology and adoptive cell therapy of Epstein-Barr virus-associated lymphoproliferative disorders in recipients of marrow allografts. Immunol Rev 157:195-216

    PubMed  Google Scholar 

  112. Gustafsson A et al (2000) Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: Prophylactic infusion of EBV-specific cytotoxic T cells. Blood 95(3):807-814

    PubMed  CAS  Google Scholar 

  113. Rooney CM et al (1998) Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 92(5):1549-1555

    PubMed  CAS  Google Scholar 

  114. Wagner HJ, Rooney CM, Heslop HE (2002) Diagnosis and treatment of posttransplantation lymphoproliferative disease after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 8(1):1-8

    PubMed  CAS  Google Scholar 

  115. Gottschalk S et al (2001) An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs. Blood 97(4):835-843

    PubMed  CAS  Google Scholar 

  116. Nalesnik MA et al (1997) Autologous lymphokine-activated killer cell therapy of lymphoproliferative disorders arising in organ transplant recipients. Transplant Proc 29(3):1905-1906

    PubMed  CAS  Google Scholar 

  117. Haque T et al (1998) Reconstitution of EBV-specific T cell immunity in solid organ transplant recipients. J Immunol 160(12):6204-6209

    PubMed  CAS  Google Scholar 

  118. Haque T et al (2007) Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: Results of a phase 2 multicenter clinical trial. Blood 110(4):1123-1131

    PubMed  CAS  Google Scholar 

  119. Gandhi MK et al (2007) Immunity, homing and efficacy of allogeneic adoptive immunotherapy for posttransplant lymphoproliferative disorders. Am J Transplant 7(5):1293-1299

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Abramson Cancer Center, Hematologic Malignancies Program, University of Pennsylvania Medical Center, Philadelphia, PA, USA

    Ran Reshef, Alicia K. Morgans & Donald E. Tsai

Authors
  1. Ran Reshef
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alicia K. Morgans
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Donald E. Tsai
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. University Hospitals Case Medical Center, Cleveland, OH, USA

    Hillard M. Lazarus

  2. Case Western Reserve University, Cleveland, OH, USA

    Mary J. Laughlin

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Reshef, R., Morgans, A.K., Tsai, D.E. (2010). Post-transplant Lymphoproliferative Disorder. In: Lazarus, H.M., Laughlin, M.J. (eds) Allogeneic Stem Cell Transplantation. Contemporary Hematology. Humana Press. https://doi.org/10.1007/978-1-59745-478-0_34

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-478-0_34

  • Published:

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-934115-33-6

  • Online ISBN: 978-1-59745-478-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation